PTC Therapeutics price target raised to $43 from $31 at Barclays
Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $43 from $31 and keeps an Equal Weight rating on the shares. The ...
BioSpace13h
After Decades of Failure, First Disease-Modifying Huntington’s Treatment on the Horizon
The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...
PTC Therapeutics (PTCT) Receives a Hold from Barclays
In a report released on November 8, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a ...